Improving Cancer Survival By Optimising Drug Exposure At Sites Of Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
The metastatic spread of cancer is responsible for 90% of cancer related deaths. While the standard of care is to administer high doses of toxic drugs to kill the cancer, this often leads to life threatening side effects without guarantee of a cure. This work is aimed at identifying how nanometer sized chemotherapeutic ‘nanomedicines’ can be optimally developed to enhance drug targeting towards sites of tumour growth and metastasis and maximise therapeutic success whilst limiting side effects.
Optimising The Therapeutic Efficacy Of Protein-based Drugs Against Lymph-resident Diseases
Funder
National Health and Medical Research Council
Funding Amount
$348,330.00
Summary
Effective treatments for lymphatic diseases (such as HIV and lymph-metastatic cancers) are limited by the lack of drug assess towards the lymphatic sites of disease progression. Improving the access of drugs into lymph therefore has the significant potential to improve the treatment of these illnesses. We will therefore explore a novel approach to improving the lymphatic uptake and retention of protein-based drugs using a useful and widely used biologically compatible polymer.